Obermatt
See Similar Stocks →

Flags

Earnings warning

Catalyst Pharmaceuticals

NAQ:CPRX · US14888U1016
BiotechnologyMedium

360

96
EV / EBIT92
Price / Owner Earnings8
Owner Earnings Yield96
Dividend Yield1
Price/Sales62
EV / Gross Profit82
Price/Book44
Return on Capital97
Cash Return on Capital92
Return on Equity88
EBIT Margin96
Gross Profitability72
Accruals56
Owner Earnings Margin94
Sales growth29
Profit Growth96
Long-Term EPS Growth54
Reinvestment49
Price momentum40
Debt load93
Refinancing80
Debt Payback100
Liquidity—
Analyst ratings3
Opinion Changes3
Price Target Upside10
Market mood73
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Catalyst Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQCM
Founded2006
Employees145
Websitecatalystpharma.com
ISINUS14888U1016
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyChronic DiseasesNeurologyCentral Nervous SystemBiotechnologyHealth CareHealth DiagnosticsPharmaceutical

Description

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The company is focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to trea…

Analysis

Quality compounder

Catalyst Pharmaceuticals, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is attractive. The owner-earnings multiple stands at 14.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 2% a year, against analyst forecasts of 12%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Catalyst Pharmaceuticals with its peers
Xenon Pharmaceuticals
NMQ:XENE
28
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioCryst Pharmaceuticals
NSQ:BCRX
52
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Spero Therapeutics
NSQ:SPRO
77
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Amicus Therapeutics
NMQ:FOLD
48
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →